Recombinant Human Interleukin-2
Acute Lymphocytic Leukemia (ALL)
Masonic Cancer Center, University of MinnesotaN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Acute Lymphocytic Leukemia (ALL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Leland Metheny | Phase 2 | B |
Azacitidine Calithera Biosciences, Inc | Phase 1 | CC |
Telaglenastat Calithera Biosciences, Inc | Phase 1 | CC |
Terameprocol Erimos Pharmaceuticals | Phase 1 | C |
Same molecule, other indications
Recombinant Human Interleukin-2 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →